• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS COAGUCHEK ® XS SYSTEM; PROTHROMBIN TIME TEST STRIPS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS COAGUCHEK ® XS SYSTEM; PROTHROMBIN TIME TEST STRIPS Back to Search Results
Catalog Number 04625374160
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Loss of Vision (2139); Confusion/ Disorientation (2553)
Event Date 10/19/2022
Event Type  Injury  
Event Description
We received an allegation that the coaguchekxs meter with serial number (b)(4) may have contributed to a patient's stroke.The patient initially called because they were following up on a request to return a meter as they had already received the replacement meter.During the call, the patient mentioned that they suffered a stroke.On (b)(6) 2022 at 8:30 am, the meter result was reportedly 3.4 inr.The laboratory result at 9:15 am was reportedly 2.8 inr.On (b)(6) 2022, the patient reportedly could not figure out how to use the phone and was confused but the patient just reportedly went to bed.The patient reportedly thinks that this was the time of the stroke.The patient reportedly could not see completely in the left eye on (b)(6) 2022.The patient reportedly drove to go to the eye doctor.The patient was reportedly sent by the eye doctor to the emergency room (er).The patient was reportedly diagnosed to have a stroke through magnetic resonance imaging (mri).The patient was reportedly admitted to the hospital from (b)(6) 2022 through (b)(6) 2022.The patient stated that they increased the warfarin dose in the hospital and they monitored the inr every day.The patient stated that they were not sure what caused the stroke.On (b)(6) 2022, the laboratory result was reportedly 3.5 inr.The patient declined to provide any further information.The therapeutic range was requested but not provided.This mdr is being submitted with an abundance of caution.
 
Manufacturer Narrative
The reporter's meter was provided for investigation where it was tested using retention strips and retention controls.Testing results (qc range = 4.1 - 6.8 inr): (b)(6).The obtained qc values were in the allowed range of the used combination strip lot - qc lot.All measurements were without error messages.According to the meter memory, the reported meter result of 4.0 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 5.7 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 2.0 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 3.5 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 4.9 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 2.8 inr on (b)(6) 2022 was obtained on (b)(6) 2022.According to the meter memory, the reported meter result of 3.4 inr on (b)(6) 2022 was obtained on (b)(6) 2022.On a regular basis, coaguchek strips of lots currently valid in the market are tested as part of routine retention testing and results have passed the internal inspection. per product labeling: "coaguchek method uses human recombinant thromboplastin.Therefore, the comparability to tests using other human recombinant thromboplastins is best, whereas higher deviations can occur with other thromboplastin types.However, those higher differences between thromboplastins of different (rabbit, bovine) origin are not an issue specific for coaguchek assays.Similar differences can be observed when a human recombinant thromboplastin-based laboratory method is compared with several other (rabbit, bovine) laboratory methods."  the investigation did not identify a product problem.The cause of the event could not be determined.  occupation: patient/consumer.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
COAGUCHEK ® XS SYSTEM
Type of Device
PROTHROMBIN TIME TEST STRIPS
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhoferstrasse 116
na
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
amy nelson
9115 hague road
na
indianapolis, IN 46250
3174767531
MDR Report Key15845573
MDR Text Key304135033
Report Number1823260-2022-03736
Device Sequence Number1
Product Code GJS
UDI-Device Identifier00365702127104
UDI-Public00365702127104
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K062925
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer
Reporter Occupation Other
Type of Report Initial
Report Date 11/22/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/22/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Expiration Date10/31/2023
Device Catalogue Number04625374160
Device Lot Number60124921
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/04/2022
Date Manufacturer Received10/26/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
WARFARIN
Patient Outcome(s) Other; Life Threatening; Hospitalization;
-
-